drugset
drugset / Trial / NCT01358084

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM

NCT01358084 ↗

Phase 2 Completed 137 enrolled AGC Biologics S.p.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of the trial is to document the efficacy of NGR-hTNF administered as maintenance treatment at 0.8 µg/m2 weekly in advanced malignant pleural mesothelioma

Timeline

Start
2011-03
Primary completion
2018-12-05
Completion
2018-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject NGR-hTNF Protein / enzyme biologic 0.8 ug/m2 Intravenous

Indications

malignant pleural mesothelioma